- Home
- KULR vs SGMT Comparison
KULR vs SGMT Comparison
Compare KULR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KULR | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 164.6M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KULR | SGMT |
|---|---|---|
| Price | $2.84 | $5.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $40.00 | $27.00 |
| AVG Volume (30 Days) | ★ 1.1M | 424.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 45.49 |
| EPS | ★ N/A | N/A |
| Revenue | $1,274,028.00 | ★ $2,000,000.00 |
| Revenue This Year | $64.40 | N/A |
| Revenue Next Year | $105.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.73 |
| 52 Week High | $7.49 | $11.41 |
Technical Indicators
Market Signals| Indicator | KULR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 46.99 |
| Support Level | $2.62 | $4.97 |
| Resistance Level | $3.13 | $6.72 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 22.96 | 33.63 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.